-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Corey Langer
-
TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse
By Kara Nyberg, PhD Posted: June 24, 2020 New findings from the TRACERx lung study underscore the value of using circulating tumor DNA (ctDNA) to predict NSCLC relapse postsurgery based on the detection of minimal residual disease (MRD). Moreover, the results appear sufficiently robust to begin to support use of ctDNA as a biomarker for…
-
A Balancing Act: Managing Patients’ Expectations
By Leah Lawrence Posted: December 11, 2019 Many patients newly diagnosed with lung cancer have difficulty navigating the world of cancer when unexpectedly and unwillingly thrust into it. In addition to understanding their diagnosis, prognosis, and treatment options, patients are also bombarded with an abundance of information on the internet, direct-to-consumer advertising of new cancer…
-
2019 IASLC World Conference on Lung Cancer Updates
Posted: November 12, 2019 More than 7,700 delegates from around the world attended the IASLC 2019 World Conference on Lung Cancer (WCLC). With sessions and workshops on every aspect of thoracic oncology patient care, the conference offered attendees from all specialties an opportunity to learn about novel research and hear from the field’s top experts.…